本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。 關閉
The extended program aims provide 10,000 free consultations across 16 villages in Cugenang district affected by 2022 earthquake The eight-week mobile clinic services program to deploy pilot Pain Phone unit to facilitate telehealth consultation JAKARTA, Indonesia, May 29, 2023 /PRNewswire/ -- Following the success of the Panadol Klinik Cekatan initiative, Haleon, a global leader in consumer health and maker of Panadol, and Halodoc, one of Indonesia's leading digital health ecosystem, revealed their next stage in tackling medical care access barriers through their mobile clinic services partnership. The extended program aims to reach people with limited mobility and access to medical consultation and treatment, focusing on the people affected by the November 2022 Cianjur earthquake. The mobile clinic services program will be aided by the Panadol Pain Phone, a first-of-its-kind telemedicine unit, bridging the distance between rural communities and medical experts using technology. (Dari kiri ke kanan) Dhanica Mae Tiu (General Manager Haleon Indonesia), Setiaji (Chief of Digital Transformation Office Kementerian Kesehatan Republik Indonesia), Yudith Arianda (Marketing Lead Haleon Indonesia), dan dr. Irwan Heriyanto, MARS (Chief of Medical Halodoc) pada peluncuran program Panadol Klinik Cekatan Tahap 2 dan Telepon Panadol Cekatan. Haleon, pemimpin global dalam kesehatan konsumen dan produsen Panadol, bekerja sama dengan Halodoc, mengumumkan peluncuran Telepon Panadol Cekatan di Jakarta hari ini (29/5). Terinspirasi oleh telepon umum konvensional, unit telehealth ini memiliki fitur seperti layar video untuk interaksi tatap muka dan sensor pengukur detak jantung, tekanan darah, suhu, dan kadar oksigen. Teknologi tersebut akan digunakan pertama kali di Cianjur untuk menjangkau komunitas yang terkena dampak gempa 2022. Menyusul kesuksesan program Panadol Klinik Cekatan, Haleon, pemimpin global dalam kesehatan konsumen dan produsen Panadol, bersama Halodoc, terus meningkatkan akses perawatan kesehatan bagi masyarakat Indonesia di pedesaan. Perluasan program ini mencakup peluncuran Telepon Panadol Cekatan, yang menyediakan upaya preventif dan kuratif melalui konsultasi medis, resep dokter, dan pengiriman obat. With 43% of Indonesians living in rural areas[1], access is a key consideration when having to choose between enduring the physical and emotional burden of pain or making a long journey to get medical care. Among these rural communities, people displaced by the earthquake may find themselves in a more dire situation as they face not only access barriers due to poor road conditions, but are also potentially undergoing skin problems, respiratory infections and digestion issues as current living conditions in temporary tent housing also limit access to clean water. In recognition of the emergent situation, the eight-week Panadol Klinik Cekatan program, complemented by the Panadol Pain Phone, will be deployed to reach 10,000 people across 16 villages in the Cugenang district, providing both preventive and curative measures through medical consultation, treatment prescription and medication delivery. Similar to the free consultations and medicine provided by the mobile clinic teams, the Pain Phone is designed to enable medical consultation and vital signs checks, while the accompanying medical team assists patients with its use as well as distribution of basic medication. The mobile telehealth unit incorporates key devices to make the consultation personal and reliable through a video screen for face-to-face interactions, as well as sensors that measure metrics such as heart rate, blood pressure, temperature, and oxygen levels. The unit is also intended as a test-and-learn pilot program with improvements and adjustments to be made for subsequent phases based on learnings from the field. Setiaji, Chief of the Digital Transformation Office, Ministry of Health, said: "Through the six pillars of transformation, we believe that digitalization is one of the keys to making healthcare more inclusive. The Panadol Klinik Cekatan and Pain Phone program by Haleon and Halodoc is a real example of how we can participate in accelerating health access throughout the country and making healthcare and health education accessible to more people." Dhanica Mae Tiu, General Manager, Indonesia, Haleon, said: "At Haleon, we are committed to do more to tackle barriers that stand in the way of people's better everyday health. We do so by understanding what holds people back from better everyday health so we can include them in opportunities to improve their health and that of their loved ones. Enabling easier and faster access to medical care is critical when millions of Indonesians are found to be delaying treatment because medical care is too far away for them. Through our continued and concerted efforts with Halodoc, we remain focused in bringing access to affordable and high-quality health care as well as empowerment through self-care promotion – this time using technology to bring remote consultation solutions to rural communities as well as people direly affected by the earthquake." dr. Irwan Heriyanto, MARS, Chief of Medical Halodoc, explained, "There is a need to continue our efforts to enhance public health literacy in Indonesia, specifically in smaller cities and underserved communities. Hence, apart from providing free health consultations and basic medication, Halodoc supports Panadol Klinik Cekatan by providing education on the importance of basic healthy lifestyle and self-care treatment. The introduction of the Pain Phone service is yet another step forward in our collaborative outreach efforts with Haleon to simplify access to healthcare through technology. We hold an optimistic view that this partnership can play a significant role in improving the overall health of Indonesians." To date, the Panadol Klinik Cekatan program has made over 7,000 free consultations, connecting people with experts to diagnose their pain, including those suffering from headaches, joint and muscle pains, as well as conditions such as hypertension, anorexia, and asthma, which can be life-threatening conditions if treatment is delayed. As the partnership continues, more outreach efforts are planned to expand the mobile clinic's coverage to other rural areas and help bridge the access gap for more people across Indonesia. [1] Source: The World Bank, 2021 https://data.worldbank.org/indicator/SP.RUR.TOTL.ZS?locations=ID
SUZHOU, China, May 29, 2023 /PRNewswire/ -- On May 26, 2023, the "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration," meticulously planned by Hillgene Biopharma and Biovalley, was successfully held at the DoubleTree by Hilton in Wuzhong District, Suzhou. The event was well-attended, with regulatory experts, scientific researchers from academic associations, professional investors from capital institutions, and industry-leading corporate leaders gathered to discuss the future of cell therapy. Opening Address Zhang Dan, the co-founder and co-chairman from Jiangsu Hillgene Biopharma Co., Ltd., served as the host and gave a speech at the opening ceremony of the conference. "This is the 1st summit of CELL WORLD, and Hillgene Biopharma will host this summit in the long term. Each event will focus on a common concern, addressing the challenges faced by the industry and unmet clinical needs, offering a stage-wise solution through the summit. The solution could be an answer in terms of commercialization, regulatory policy or economy, or an answer concerning the above two or more." Li Hongjian, the founder, chairman, and CEO of Jiangsu Hillgene Biopharma Co., Ltd., delivered the opening speech. "As a leading professional CDMO company focused on cell therapy, since its establishment, Hillgene Biopharma has exceeded a total service order of over RMB 530 million, 100% of which were for cell therapy projects (including 34 new drug projects from academicians' teams), covering advanced therapies such as CAR-T, CAR-NK, and TCR-T. We have successfully filed IND for 8 projects, with 2 registered clinical projects underway.In terms of international footprint, our company has supported 4 projects for FDA & EMA orphan drug designations. I hope this 1st CELL WORLD Global Cell Therapy Summit will further promote the development and innovation of cell therapy industry globally and provide more thoughts and practical examples." Keynote Speeches Dr. Fan Xiaohu, founder and CEO of Wondercel Biotech and former Chief Scientist of Legend Biotech, gave an opening keynote report titled "How Do Cell Therapy Products Participate in International Competition". Zhao Yuan, CTO of Jiangsu Hillgene Biopharma Co., Ltd., expert of the European Medicines Agency (EMA), and former Director of the Gene Therapy Division of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, shared strategies from the perspective of EU regulation on the CMC of cell therapy drugs in her speech titled "CMC Strategy of Cell Therapy Drug from the Perspective of EU Regulation". Dr. He Xuhua, Director of the Department of Hematopathology at Duke University School of Medicine and Lifetime Professor of Hematologic Diagnosis at MD Anderson Cancer Center in the US, delivered a report titled "Best Oncology Practice for Implementation of CAR-T Therapy in DLBCL and Myeloma - From Novel Data to Multidisciplinary Clinical Care". Lv Xiaobin, a former senior review expert at the FDA and the chief reviewer of CMC for Novartis' CAR-T drug Kymriah's BLA, shared in his report "Viewing Cell Therapy Drug Registration in the United States from a Review Perspective," the challenges encountered during the drug registration process, and how to combine different tools to overcome these obstacles and gain approval smoothly. Signing Ceremony for Strategic Cooperation A signing ceremony for strategic cooperation was held concurrently in this forum. Representatives of Jiangsu Hillgene Biopharma Co., Ltd. successfully signed contracts with Shanghai NK CellTech Co., Ltd., TCRx (Nanjing) Therapeutics Co.Ltd, and Suzhou VDO Biotech Co., Ltd., to jointly promote the efficient progress of cooperative projects and achieve mutual benefits. Round Table Discussion The round table discussion, themed "Cell Therapy Clinical Research and Development Strategy Guided by Clinical Demand," was hosted by Dr. Cai Xuejun, Vice President of Global R&D and Head of China R&D Department at Bristol-Myers Squibb. Participants included Dr. Zheng Xiaonan, Executive Vice Chairman and Secretary-General of the China Biopharmaceutical Industry Chain Innovation Transformation Alliance, Dr. Zhu Chouwen, Director of Shanghai Clinical Research Center and President of Shanghai University of Science and Technology Research Hospital, Dr. Zhou Huan, Dean of the Clinical Trial Technology Academy of Anqing Medical College and Director of the Clinical Trial Research Center of The First Affiliated Hospital of Bengbu Medical College, Dr. Tian Xiaopeng, Deputy Chief Physician of Hematology Department of the First Affiliated Hospital of Soochow University, and Dr. Zhou Jiawei, Research Doctor at the GCP Center of Cancer Hospital Chinese Academy of Medical Sciences. Executive Seminar The executive seminar, themed "Cell Therapy Development Strategy Aiming for International Success," was chaired by Dr. Zhang Dan. The attendees actively expressed their opinions, having a thorough exchange and in-depth discussion about the challenges in the field of cell therapy. After the summit, all the attendees took a group photo for memorabilia. The "CELL WORLD 1st Global Cell Therapy Summit and Hillgene Biopharma Anniversary Celebration" came to a perfect end amid the laughter and joy of the banquet. We thank all the participants, the organizers, and all the behind-the-scenes staff for their hard work. Hillgene Biopharma will continue to follow closely the development of the biopharmaceutical field, always adhering to the vision of "letting cell therapy write a new chapter of life," focusing on providing cell therapy solutions for the industry, striving for perfection, and committed to pushing more cell therapies to the market to benefit more patients. Hillgene Biopharma sincerely looks forward to moving ahead with all the participants in the field of cell therapy, and hopes to have more collaborations in the industry to stride towards a bright and splendid future.
STOCKHOLM, May 29, 2023 /PRNewswire/ -- 200 tonnes of waste are generated in the Mount Everest region every year. That is why Sagarmatha Next, an experience centre at 3,775 meters on the foot of Mount Everest, is dedicated to raising awareness on the issues through art and design. Sagarmatha Next is now releasing a new film to help raise awareness and support for the important cause of keeping Mount Everest free from waste. Mount Everest trash, photo by Martin Edström "We are excited to celebrate our first anniversary and the release of our new film. The film shows how this remote region attracts thousands of visitors and how we must all come together to preserve it for future generations," said Varun Saraf, Director at Saraf Foundation and founder of Sagarmatha Next. With 80,000 yearly trekkers visiting Sagarmatha National Park, approx. 200 tonnes of solid waste are generated. Given the lack of infrastructure and connectivity, this waste is left behind in the mountains. Sagarmatha Next works with the local NGO SPCC to find innovative ways to remove and upcycle waste from the mountains. Started in 2019, carry me back is a crowdsourced waste removal system, that offers every trekker an opportunity to remove 1 kg of waste from the mountains. The program has successfully removed 10,000 kg with the help of 6,000 participants who have voluntarily carried them out of the national park. Powered by DELL Technologies, the high-altitude experience centre Sagarmatha Next has become a must-stop for visitors. Since opening, more than 15,000 visitors have been educated about the challenges in the region and the initiatives to solve them, and enjoyed the interactive digital exhibition and several VR experiences that transports visitors to the highest peaks. Sagarmatha Next is excited to announce the release of its new film that showcases the impact of tourism and waste in the region and hopes it inspires further action globally. "The entire world comes to Everest, the highest place on earth and this is where the change begins. We wish to spread the message and replicate projects to remove waste to other environment-sensitive regions across the globe," says Varun Saraf. More information about the film can be found here: https://youtu.be/Jgg8P2KGSMU. For further information, contact: Eva Villardón GrandeGeneral Manager Marketing & Communicationcommunications@sagarmathanext.com+9779822382388
BEIJING, May 29, 2023 /PRNewswire/ -- There are two cities in North China's Xiong'an New Area, or dubbed as China's "city of the future" -- one is the city above the ground, and the other is the city in high-tech "cloud". Yuan Xiaodong, CTO of Xiong'an Yunwang Technology Co, has joined the construction of Xiong'an Urban Computing Center since the plan was first proposed in 2020, and was hailed as being "city brain". "I have put all my past experience on this project, and what I dared not to do in the past can be realized here," Yuan told the Global Times. Yuan said that the project is part of the city's blueprint as the city is designed to become an intelligent city featuring high-tech innovations since its inception. On April 1, 2017, China announced plans to establish Xiong'an New Area in North China's Hebei Province about 100 kilometers south of Beijing, in what an official statement called "a strategy that will have lasting importance for the millennium to come and a significant national event."For a city whose establishment will carry "lasting importance for the millennium to come," China's central authorities have stressed the importance of planning and designing, saying "every inch of land should be clearly planned before construction," according to the official Xinhua News Agency. China's leadership also stated to build the city, leveraging advanced science and technology, in a bid to make innovative advances the trademark of Xiong'an New Area.Futuristic city To realize the ambitions of "city of the future," Xiong'an New Area was being constructed via digital and real programming at the same time, and even every building and street light in the city has a one-to-one correspondence as part of a highly digitalized city. With a total investment of 1.099 billion yuan ($156 million), the Xiong'an Urban Computing Center carries supercomputing and cloud computing facilities, and provides network, computing, and storage services for big data, blockchain, Internet of Things, AI, and VR/AR covering the entire city. The center will be a center to carry four platforms for the city, including an integrated data platform, video network platform, city information modeling platform and Internet of Things (IOT) platform. All the big data of the platforms will form a collection, and being analyzed via computing power and big data analysis tools to provide decision-making basis for Xiong'an's urban construction and future urban operations, and ultimately serve the daily operations of the entire city. The ambitious digital construction avoids the complexities of "information islands" and will help solve problems such as data incompatibility among various departments in the city, Yuan said. "Our server software instructions, network components, server components, and security components in this center are all self-developed by ourselves," Yuan said, proudly. The Xiong'an Urban Computing Center was put into operation in April this year, and is only one part of the extensive network of technology being built in the city. Smart constructionAt the construction site of the Xiong'an Xuanwu Hospital project, a high-definition camera with a 23x zoom is installed in the project control room, which can focus on safety belt buckles of workers on a scaffolding jungle about 500 meters from surface.In the Xiong'an Citizen Service Center, each component is merged with a chip or posted a QR code, which realizes big data management of the whole process. The project also uses the big data center as a hub, and incorporates a smart construction system. The contractor only needs a computer or mobile phone to realize panoramic monitoring, energy consumption monitoring and drone aerial photography, according to China State Construction Co.The citizen service center has been connected to many smart devices at the earliest stage of design. Although the construction schedule is tight, the digital application in the process of construction has been a big help to quality control, Yin Yunhui, a technician from China State Construction told the Global Times. Since the establishment of Xiong'an New District, blockchain technology has been applied to urban design, including the management of the wages for every construction worker onsite, and it can be said that blockchain technology has been integrated into all aspects of the construction of the city. "To avoid the risk of interception or misappropriation of funds, we have developed a blockchain system for public fund management, relying on the information flow on the blockchain to drive capital flow to realize accurate, timely and transparent disbursement of funds," Meng Hongwei, deputy director of Xiong'An Blockchain Lab with Intelligent City Innovation Federation, told the Global Times. Now, there are more than 400 projects covering more than 4,000 enterprises registered in local industrial service platform aided with the blockchain technology to make payment, Meng added. The city's blockchain lab, which was set up in 2020 with the goal of applying blockchain technology to aid the construction of a new and smart city, also highlights Xiong'an's focus on technological innovation. Xiong'an New Area launched the digital yuan pilot project at the end of 2019, with many use scenarios including the banks and inner-city supermarkets, hotels and e-commerce platforms trialing out the digital yuan. Over a development span of more than six years, the city has completed a cumulative investment of 530 billion yuan by the end of 2022, and more than 3,600 buildings have been erected. The city has also rolled out 3,536 5G base stations, realizing full coverage of 5G networks in the city.As the first experimental area in China to adopt smart transportation, the total mileage of digitalized road in Xiong'an will be expanded to 500 kilometers, and currently, the total mileage of digital roads has reached more than 200 kilometers. And, relying on "5G+Beidou" positioning, the city's public transport system will become increasingly intelligent. "Xiong'an is to be a leader in innovation, offering endless possibilities and opportunities," Yuan said.
SHANGHAI, May 29, 2023 /PRNewswire/ -- Growatt, a world-renowned provider of distributed energy solutions, has concluded its successful participation at the SNEC PV Power Expo in Shanghai. The company's achievements were highlighted by its receipt of the Top Brand PV 2023 award from EUPD Research, along with the showcase of an impressive array of cutting-edge energy solutions. Growatt Shines at SNEC Exhibition with Top Brand Awards and Cutting-Edge Solutions Top Brand PV Awards The Top Brand PV 2023 award further solidifies Growatt's leading status in the industry, with a dominant presence in the residential sector and a prominent standing among the top three global players in the commercial and industrial (C&I) market. "We are delighted to award Growatt as a Top Brand PV 2023 for multiple key markets, reflecting the company's ongoing performance and dedication to driving the energy transition on an international level," commented Daniel Fuchs, Vice President of EUPD Research at the award handover ceremony. Full Range Battery Ready Solutions One of the highlights of Growatt's exhibition was the comprehensive suite of battery-ready solutions. With capacities from 2.5 to 30 kW, the solutions empower households worldwide to adopt low-carbon lifestyles by providing the flexibility to integrate battery systems at a later time. By combining the battery-ready inverters with the latest APX HV battery, homeowners gain enhanced control over their energy management, increasing solar self-consumption and elevating overall system safety. Solar Energy Solutions for Businesses The brand's advancements in C&I energy storage systems were also on display, featuring the WIT inverters and APX commercial batteries. The WIT series 50-100kW storage inverters, boasting advanced functions such as built-in UPS, black start capability, 100% unbalanced output, and 110% continuous AC overloading, work seamlessly with the APX Commercial battery. This powerful combination empowers businesses to achieve energy independence while optimizing operational efficiency. Innovations for Vast Application Scenarios To address diverse energy needs, Growatt impressed attendees with its revolutionary NEO 2000M-X, a flexible and scalable micro-inverter that not only prioritizes high yields with four MPP trackers and a maximum efficiency of 96.5% but also supports long signal transmission distance with Lora communication. Additionally, the innovative portfolio of off-grid products, THOR EV chargers, and portable power stations exemplify the manufacturer's ongoing efforts to provide sustainable energy solutions across various application scenarios.
TAMPA, Fla., May 29, 2023 /PRNewswire/ -- The US FDA, on the 24th of May 2023, granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc's Sirolimus Coated Balloon (SCB) MagicTouch PTA for the treatment of Superficial Femoral Arteries (SFA). This marks the fourth IDE approval for the Company's Sirolimus coated balloon. Concept Medical's fourth IDE approval for the MagicTouch Sirolimus Coated Balloon is granted for the treatment of Superficial Femoral Artery Disease (SFA) The Company has already received three other pivotal IDE approvals for its SCB MagicTouch family of products for the coronary In-Stent Restenosis (ISR), Coronary Small Vessel and Below-the-Knee indications. Lower extremity Peripheral Arterial Disease (PAD) affects an estimated quarter million adults in Europe and North America and is associated with significant morbidity and mortality, with atherosclerosis being the main cause. Stenosed and occluded SFA remain major contributors to the PAD. The IDE approval will allow Concept Medical to initiate pivotal clinical study to demonstrate safety and effectiveness of the MagicTouch PTA Sirolimus coated balloon in femoral and popliteal segments. The data generated from this IDE clinical study will support a future pre-market approval (PMA) application in the USA. MagicTouch PTA is the world's first Sirolimus coated balloon with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets. It is also the most clinically studied Sirolimus Drug Coated Balloon (DCB) for PAD treatment, which includes the largest head-to-head RCT against Paclitaxel DCB, and the largest RCT against uncoated balloon. Presently, the treatment options for PAD are limited to uncoated PTA balloons, paclitaxel coated DCBs and a DES, thus restricting the physician's choice and alternatives for patients. Uncoated balloons have been identified with substandard results post intervention due to recurrent re-narrowing of arteries, and Paclitaxel safety remains a debate due to association of the drug with long-term mortality. Sirolimus which has already proven safety in coronary artery disease treatment, will fill this gap in PAD of safety and efficacy in near future. "We are extremely proud to have received the 4th IDE approval from the USFDA for MagicTouch PTA in the SFA indication," said Dr. Manish Doshi, Founder and M.D. - Concept Medical Group. "This milestone underscores our unwavering commitment to advancing medical technology and providing innovative solutions that have the potential to transform patient care." About MagicTouch PTA: MagicTouch PTA is a CE approved and commercially marketed Sirolimus coated balloon outside the United States of America for the treatment of de-novo, stenotic and in-stent restenotic lesions in Superficial Femoral (SFA), popliteal, Below The Knee (BTK) and iliac arteries, using proprietary Nanoluté Technology. About Concept Medical Inc. (CMI): CMI is headquartered in Tampa, Florida and has operational offices in The Netherlands, Singapore and Brazil and manufacturing units in India. CMI specializes in developing unique combination products with patented coating technology that can deliver any drug / pharmaceutical agent across the luminal surfaces of blood vessels.
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎?立即 加入台灣產經新聞網會員 ,使用免費新聞發佈服務。 (服務項目) (投稿規範)